{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:23:57Z","timestamp":1777605837425,"version":"3.51.4"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atrial fibrillation (AF) is a cardiac arrhythmia characterized by disorganized atrial electrical activity, resulting in ineffective mechanical contraction and a heightened propensity for intra-atrial thrombus formation. The underlying pathophysiology is multifactorial, involving a complex interplay of pro-fibrotic, inflammatory, and pro-thrombotic pathways, notably oxidative stress and dysregulation of the fibrinolytic system. Given that these mechanisms remain incompletely elucidated, this study sought to investigate the association between biomarkers of oxidative stress and antifibrinolytic activity in AF patients treated with the oral anticoagulants warfarin or rivaroxaban, in comparison to a healthy control cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 85 AF patients\u201438 on rivaroxaban and 47 on warfarin\u2014were enrolled alongside 62 matched healthy controls. Cellular metabolic activity was assessed via MTT [3-(4,5-Dimethylthiazol-2\u03b3l)-2,5-Diphenyl Tetrazoline Bromide] assay measured by spectrophotometry. Serum concentrations of thiobarbituric acid reactive substances (TBARS, a marker of lipid peroxidation), plasminogen activator inhibitor-1 (PAI-1), and thrombin-activatable fibrinolysis inhibitor (TAFI) were quantified using enzyme-linked immunosorbent assay (ELISA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The rivaroxaban group exhibited significantly greater MTT absorbance, indicative of enhanced cellular metabolic activity, and significantly lower circulating TAFI levels compared to the warfarin group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These results suggest that in patients with AF, rivaroxaban may provide pleiotropic benefits beyond anticoagulation, potentially by augmenting cellular antioxidant mechanisms and suppressing antifibrinolytic activity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1685101","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T09:15:11Z","timestamp":1768814111000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Rivaroxaban versus warfarin: differential effects on oxidative stress and fibrinolytic markers in atrial fibrillation"],"prefix":"10.3389","volume":"17","author":[{"given":"Helton Jose","family":"Reis","sequence":"first","affiliation":[{"name":"Departamento de Farmacologia, Instituto de Ci\u00eancias Biol\u00f3gicas (ICB), Universidade Federal de Minas Gerais","place":["Belo Horizonte, Minas Gerais, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luana Bernardes Xavier","family":"Costa","sequence":"additional","affiliation":[{"name":"Faculdade de Farm\u00e1cia, Universidade Federal de Minas Gerais","place":["Belo Horizonte, Minas Gerais, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela Lopes","family":"Martins","sequence":"additional","affiliation":[{"name":"Departamento de Farmacologia, Instituto de Ci\u00eancias Biol\u00f3gicas (ICB), Universidade Federal de Minas Gerais","place":["Belo Horizonte, Minas Gerais, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita Carolina Figueiredo","family":"Duarte","sequence":"additional","affiliation":[{"name":"Faculdade de Farm\u00e1cia, Universidade Federal de Minas Gerais","place":["Belo Horizonte, Minas Gerais, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luma Clara Martins","family":"Costa","sequence":"additional","affiliation":[{"name":"Faculdade de Farm\u00e1cia, Universidade Federal de Minas Gerais","place":["Belo Horizonte, Minas Gerais, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Est\u00eav\u00e3o Lanna","family":"Figueiredo","sequence":"additional","affiliation":[{"name":"Hospital Lifecenter","place":["Belo Horizonte, Minas Gerais, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Rezende","family":"Silveira","sequence":"additional","affiliation":[{"name":"Hospital Semper","place":["Belo Horizonte, Minas Gerais, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nath\u00e1lia Greco","family":"Coelho","sequence":"additional","affiliation":[{"name":"Faculdade de Farm\u00e1cia, Universidade Federal de Minas Gerais","place":["Belo Horizonte, Minas Gerais, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria das Gra\u00e7as","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Faculdade de Farm\u00e1cia, Universidade Federal de Minas Gerais","place":["Belo Horizonte, Minas Gerais, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciene Bruno","family":"Vieira","sequence":"additional","affiliation":[{"name":"Departamento de Farmacologia, Instituto de Ci\u00eancias Biol\u00f3gicas (ICB), Universidade Federal de Minas Gerais","place":["Belo Horizonte, Minas Gerais, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edna Afonso","family":"Reis","sequence":"additional","affiliation":[{"name":"Departamento de Estat\u00edstica, Instituto de Ci\u00eancias Exatas (ICEx), Universidade Federal de Minas Gerais","place":["Belo Horizonte, Minas Gerais, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina Braga","family":"Gomes","sequence":"additional","affiliation":[{"name":"Faculdade de Farm\u00e1cia, Universidade Federal de Minas Gerais","place":["Belo Horizonte, Minas Gerais, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e1udia Nat\u00e1lia","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Faculdade de Farm\u00e1cia, Universidade Federal de Minas Gerais","place":["Belo Horizonte, Minas Gerais, Brazil"]},{"name":"Col\u00e9gio T\u00e9cnico, Universidade Federal de Minas Gerais","place":["Belo Horizonte, Minas Gerais, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00210-022-02319-y","article-title":"The protective effect of rivaroxaban with or without aspirin on inflammation, oxidative stress, and platelet reactivity in isoproterenol-induced cardiac injury in rats","volume":"396","author":"Abedalqader","year":"2023","journal-title":"Naunyn Schmiedeb. Arch. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1161\/01.ATV.0000228844.65168.d1","article-title":"Thrombin-cofactor interactions: structural insights into regulatory mechanisms","volume":"26","author":"Adams","year":"2006","journal-title":"Arteriosclerosis, Thrombosis, Vascular Biology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1244098","DOI":"10.3389\/fphar.2023.1244098","article-title":"Distinct pleiotropic effects of direct oral anticoagulants on cultured endothelial cells: a comprehensive review","volume":"14","author":"Atzemian","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"516","DOI":"10.36660\/abc.20201238","article-title":"Diretrizes Brasileiras de Hipertens\u00e3o Arterial\u20132020","volume":"116","author":"Barroso","year":"2021","journal-title":"Arq. Bras. Cardiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.bcp.2019.02.016","article-title":"Nox2-mediated platelet activation by glycoprotein (GP) VI: effect of rivaroxaban alone and in combination with aspirin","volume":"163","author":"Cammisotto","year":"2019","journal-title":"Biochem. Pharmacology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1160\/TH12-05-0310","article-title":"Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor","volume":"108","author":"Chan","year":"2012","journal-title":"Thrombosis Haemostasis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1093\/eurheartj\/ehy411","article-title":"A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation","volume":"39","author":"Cowan","year":"2018","journal-title":"Eur. Heart Journal"},{"key":"B8","volume-title":"Efeito do \u00e1cido acetilsalic\u00edlico na ativa\u00e7\u00e3o plaquet\u00e1ria e perfil oxidativo em pacientes com Diabetes Mellitus tipo 2","author":"Duarte","year":"2012"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/10760296241296138","article-title":"Vascular endothelial dysfunction and immunothrombosis in the pathogenesis of atrial fibrillation","volume":"30","author":"Dungan","year":"2024","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"B10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.thromres.2016.04.008","article-title":"Expression of pro-inflammatory genes in human endothelial cells: Comparison of rivaroxaban and dabigatran","volume":"142","author":"Ellinghaus","year":"2016","journal-title":"Thrombosis Research"},{"key":"B11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1160\/TH13-09-0730","article-title":"Targeting factor Xa and thrombin: impact on coagulation and beyond","volume":"111","author":"Esmon","year":"2014","journal-title":"Thrombosis Haemostasis"},{"key":"B12","volume-title":"Major Progress in Anticoagulant Uptake for Atrial Fibrillation at Last: Does it Translate Into Stroke Prevention?","author":"Freedman","year":"2018"},{"key":"B13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1055\/s-0037-1617102","article-title":"The endothelium and atrial fibrillation","volume":"28","author":"Freestone","year":"2008","journal-title":"H\u00e4mostaseologie"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1161\/HYPERTENSIONAHA.113.02360","article-title":"Oxidative stress is associated with increased pulmonary artery systolic pressure in humans","volume":"63","author":"Ghasemzadeh","year":"2014","journal-title":"Hypertension"},{"key":"B15","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/FJC.0000000000000313","article-title":"Oxidant and inflammatory mechanisms and targeted therapy in AF: an update","volume":"66","author":"Gutierrez","year":"2015","journal-title":"J. Cardiovascular Pharmacology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.13210\/j.cnki.jhmu.20190109.004","article-title":"Analysis of atrial remodeling, fibrosis, oxidative stress and insulin resistance levels in patients with atrial fibrillation","volume":"25","author":"Huang","year":"2019","journal-title":"J. Hainan Med. Univ."},{"key":"B17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00595-012-0472-6","article-title":"Late events and mid-term results after endovascular aneurysm repair","volume":"44","author":"Ishibashi","year":"2014","journal-title":"Surg. Today"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1007\/s00380-017-0962-y","article-title":"Anti-inflammatory effect of factor-Xa inhibitors in Japanese patients with atrial fibrillation","volume":"32","author":"Katoh","year":"2017","journal-title":"Heart Vessels"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American heart association\/american stroke association","volume":"45","author":"Kernan","year":"2014","journal-title":"Stroke"},{"key":"B20","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1161\/CIRCOUTCOMES.110.958165","article-title":"Estimation of total incremental health care costs in patients with atrial fibrillation in the United States","volume":"4","author":"Kim","year":"2011","journal-title":"Circulation Cardiovasc. Qual. Outcomes"},{"key":"B21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1055\/s-0040-1701206","article-title":"Effects of rivaroxaban on biomarkers of coagulation and inflammation: a post hoc analysis of the X-VeRT trial","volume":"4","author":"Kirchhof","year":"2020","journal-title":"TH Open"},{"key":"B22","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1160\/TH14-08-0653","article-title":"Pro-inflammatory cytokines reduce human TAFI expression via tristetraprolin-mediated mRNA destabilisation and decreased binding of HuR","volume":"114","author":"Komnenov","year":"2015","journal-title":"Thrombosis Haemostasis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jjcc.2017.08.007","article-title":"Possible role of rivaroxaban in attenuating pressure-overload-induced atrial fibrosis and fibrillation","volume":"71","author":"Kondo","year":"2018","journal-title":"J. Cardiology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12959-016-0111-3","article-title":"DOACs\u2013advances and limitations in real world","volume":"14","author":"Lee","year":"2016","journal-title":"Thrombosis Journal"},{"key":"B25","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/1076029616648407","article-title":"Increased level of thrombotic biomarkers in patients with atrial fibrillation despite traditional and new anticoagulant therapy","volume":"22","author":"Liles","year":"2016","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"B26","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s12276-020-0397-x","article-title":"Therapeutics targeting the fibrinolytic system","volume":"52","author":"Lin","year":"2020","journal-title":"Exp. and Molecular Medicine"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3892\/ijmm.2017.3166","article-title":"Rivaroxaban attenuates thrombosis by targeting the NF-\u03baB signaling pathway in a rat model of deep venous thrombus retraction in\/10.3892\/ijmm. 2018.3565","volume":"40","author":"Ma","year":"2017","journal-title":"Int. Journal Molecular Medicine"},{"key":"B28","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fcvm.2020.00114","article-title":"Comparison of inflammatory mediators in patients with atrial fibrillation using warfarin or rivaroxaban","volume":"7","author":"Martins","year":"2020","journal-title":"Front. Cardiovasc. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.diabres.2006.12.008","article-title":"Determination of the antioxidant status of plasma from type 2 diabetic patients","volume":"77","author":"Medina","year":"2007","journal-title":"Diabetes Research Clinical Practice"},{"key":"B30","doi-asserted-by":"publisher","first-page":"7042","DOI":"10.1038\/s41467-025-62218-7","article-title":"Biomarker panels for improved risk prediction and enhanced biological insights in patients with atrial fibrillation","volume":"16","author":"Meyre","year":"2025","journal-title":"Nat. Commun."},{"key":"B31","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1080\/07853890.2018.1495337","article-title":"Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: biomarker substudy results from a prospective study with rivaroxaban (X-TRA)","volume":"50","author":"Miyazawa","year":"2018","journal-title":"Ann. Medicine"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1111\/bcp.13383","article-title":"FXa inhibition by rivaroxaban modifies mechanisms associated with the pathogenesis of human abdominal aortic aneurysms","volume":"83","author":"Mo\u00f1ux","year":"2017","journal-title":"Br. Journal Clinical Pharmacology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4140","DOI":"10.3390\/ijms20174140","article-title":"Edoxaban exerts antioxidant effects through FXa inhibition and direct radical-scavenging activity","volume":"20","author":"Narita","year":"2019","journal-title":"Int. Journal Molecular Sciences"},{"key":"B34","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.medin.2016.10.008","article-title":"Reduced thrombin activatable fibrinolysis inhibitor and enhanced proinflammatory cytokines in acute coronary syndrome","volume":"41","author":"Pang","year":"2017","journal-title":"Med. Intensiva"},{"key":"B35","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1161\/CIRCRESAHA.119.315099","article-title":"Rivaroxaban reduces arterial thrombosis by inhibition of FXa-driven platelet activation via protease activated receptor-1","volume":"126","author":"Petzold","year":"2020","journal-title":"Circ. Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.yjmcc.2024.09.011","article-title":"Oxidative stress and atrial fibrillation","volume":"196","author":"Pfenniger","year":"2024","journal-title":"J. Mol. Cell Cardiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.phrs.2016.09.035","article-title":"Anti-Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding","volume":"113","author":"Pignatelli","year":"2016","journal-title":"Pharmacol. Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"5355","DOI":"10.19102\/icrm.2023.14025","article-title":"The role of major biomarkers of stress in atrial fibrillation: a literature review","volume":"14","author":"Rafaqat","year":"2023","journal-title":"J. Innov. Card. Rhythm Manage."},{"key":"B39","doi-asserted-by":"publisher","first-page":"804","DOI":"10.4070\/kcj.2020.0055","article-title":"Effects of long-term thrombin inhibition (dabigatran etexilate) on spontaneous thrombolytic activity during the progression of atherosclerosis in ApoE\u2212\/\u2212\u2013LDLR\u2212\/\u2212 double-knockout mice","volume":"50","author":"Sanda","year":"2020","journal-title":"Korean Circ. J."},{"key":"B40","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11239-023-02776-z","article-title":"The effect of rivaroxaban on biomarkers in blood and plasma: a review of preclinical and clinical evidence","volume":"55","author":"Schiffer","year":"2023","journal-title":"J. Thromb. Thrombolysis"},{"key":"B41","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1093\/cvr\/cvt343","article-title":"Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants","volume":"101","author":"Spronk","year":"2014","journal-title":"Cardiovasc. Research"},{"key":"B42","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1055\/s-0039-1701011","article-title":"Impaired fibrinolysis predicts adverse outcome in acute coronary syndrome patients with diabetes: a PLATO sub-study","volume":"120","author":"Sumaya","year":"2020","journal-title":"Thrombosis Haemostasis"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/j.hrthm.2017.07.028","article-title":"Association between oxidative stress and atrial fibrillation","volume":"14","author":"Tahhan","year":"2017","journal-title":"Heart Rhythm."},{"key":"B44","doi-asserted-by":"publisher","first-page":"100967","DOI":"10.1016\/j.lanepe.2024.100967","article-title":"Comparing CHA2DS2-VA and CHA2DS2-VASc scores for stroke risk stratification in patients with atrial fibrillation: temporal trends analysis from the FinACAF cohort","volume":"43","author":"Teppo","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"B45","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.thromres.2016.06.008","article-title":"Rivaroxaban improves patency and decreases inflammation in a mouse model of catheter thrombosis","volume":"144","author":"Terry","year":"2016","journal-title":"Thrombosis Research"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3678017","DOI":"10.1155\/2017\/3678017","article-title":"Intracardiac hemostasis and fibrinolysis parameters in patients with atrial fibrillation","volume":"2017","author":"T\u00f3th","year":"2017","journal-title":"BioMed Research International"},{"key":"B47","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1538-7836.2008.03221.x","article-title":"Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study","volume":"7","author":"Tregouet","year":"2009","journal-title":"J. Thrombosis Haemostasis"},{"key":"B48","doi-asserted-by":"publisher","first-page":"9538","DOI":"10.3390\/nu7115479","article-title":"New insights into the pros and cons of the clinical use of vitamin K antagonists (VKAs) versus direct oral anticoagulants (DOACs)","volume":"7","author":"Van Gorp","year":"2015","journal-title":"Nutrients"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1590\/s0100-40422007000500046","article-title":"Esp\u00e9cies reativas de oxig\u00eanio e de nitrog\u00eanio, antioxidantes e marcadores de dano oxidativo em sangue humano: principais m\u00e9todos anal\u00edticos para sua determina\u00e7\u00e3o","volume":"30","author":"Vasconcelos","year":"2007","journal-title":"Qu\u00edm. Nova"},{"key":"B50","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/clc.23147","article-title":"CHA2DS2\u2010VASc score predicts atrial fibrillation recurrence after cardioversion: systematic review and individual patient pooled meta\u2010analysis","volume":"42","author":"Vitali","year":"2019","journal-title":"Clin. Cardiology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.jacc.2024.11.052","article-title":"Biomarker-based model for prediction of ischemic stroke in patients with atrial fibrillation","volume":"85","author":"Wallentin","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2174\/1573403X15666181205110624","article-title":"Gender differences in atrial fibrillation: a review of epidemiology, management, and outcomes","volume":"15","author":"Westerman","year":"2019","journal-title":"Curr. Cardiology Reviews"},{"key":"B53","volume-title":"WHO guidelines on physical activity and sedentary behaviour","year":"2020"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.3390\/ijms21061953","article-title":"The protective effect of dabigatran and rivaroxaban on DNA oxidative changes in a model of vascular endothelial damage with oxidized cholesterol","volume":"21","author":"Wo\u017aniak","year":"2020","journal-title":"Int. Journal Molecular Sciences"},{"key":"B55","doi-asserted-by":"publisher","first-page":"0124716","DOI":"10.1371\/journal.pone.0124716","article-title":"Association of hemostatic markers with atrial fibrillation: a meta-analysis and meta-regression","volume":"10","author":"Wu","year":"2015","journal-title":"PLoS One"},{"key":"B56","volume-title":"Arq Bras Cardiol","author":"Xavier","year":"2014"},{"key":"B57","doi-asserted-by":"publisher","first-page":"400","DOI":"10.20452\/pamw.1101","article-title":"Thromboembolic events are associated with prolonged clot lysis time in patients with permanent atrial fibrillation","volume":"121","author":"Z\u0105bczyk","year":"2011","journal-title":"Pol. Arch. Med. Wewn\u0119trznej"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1685101\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:36:28Z","timestamp":1771918588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1685101\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":57,"alternative-id":["10.3389\/fphar.2026.1685101"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1685101","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"article-number":"1685101"}}